文献速递血脂与心血管预防冠心病心力衰竭与心肌病

澳大利亚人群队列中高敏心肌肌钙蛋白I与心血管疾病风险

High-sensitivity cardiac troponin I and risk of cardiovascular disease in an Australianpopulation-based cohort.
PubMed 文献 · Heart · 2017-10-24

在Busselton健康研究1994/1995队列3939人中检测血清高敏肌钙蛋白I(hs-cTnI),随访20年。校正Framingham风险评分变量后,hs-cTnI每翻倍与全因死亡、心血管死亡、心血管事件、心衰和卒中风险显著相关,且无性别交互作用。

要点

  • hs-cTnI可独立预测全因死亡、心血管死亡及心血管事件。
  • 基线无心血管病人群中,除冠心病事件外关联仍显著。
  • hs-cTnI≥6.0 ng/L男性与≥4.0 ng/L女性心血管事件风险更高。

核心结论

  • 高敏法检测的肌钙蛋白I是全因死亡和心血管事件的独立预测因子。
  • hs-cTnI可能有助于在一般人群中识别高危个体。

研究设计与样本

  • 基于Busselton健康研究1994/1995队列的人群基础队列研究,共3939人。
  • 检测基线血清hs-cTnI,随访20年评估死亡与心血管结局。

主要发现

  • 基线hs-cTnI可检出(>1.2 ng/L)者占66.1%,男性81.8%,女性54.4%。
  • 随访20年共886例死亡(其中心血管死亡361例)和940例心血管事件。
  • 校正Framingham风险评分变量后,hs-cTnI每翻倍与全因死亡HR 1.16(95%CI 1.09-1.24)、心血管死亡HR 1.33(1.23-1.44)、心血管事件HR 1.18(1.11-1.25)、冠心病事件HR 1.11(1.03-1.20)、心衰HR 1.44(1.31-1.58)、卒中HR 1.13(1.03-1.24)相关。
  • 基线无心血管病人群(n=3215)中除冠心病事件外上述关联仍显著。
  • 与hs-cTnI≤1.2 ng/L者相比,hs-cTnI≥6.0 ng/L男性心血管事件HR 2.18(1.42-3.37),hs-cTnI≥4.0 ng/L女性HR 1.84(1.30-2.62)。

关键数值与推荐

  • hs-cTnI每翻倍对应全因死亡HR 1.16(95%CI 1.09-1.24)。
  • hs-cTnI每翻倍对应心血管死亡HR 1.33(95%CI 1.23-1.44)。
  • hs-cTnI每翻倍对应心衰HR 1.44(95%CI 1.31-1.58)。
  • 男性hs-cTnI≥6.0 ng/L心血管事件HR 2.18(95%CI 1.42-3.37)。
  • 女性hs-cTnI≥4.0 ng/L心血管事件HR 1.84(95%CI 1.30-2.62)。

临床怎么用

  • 在一般人群风险评估中可考虑检测hs-cTnI以辅助识别心血管高危个体。
  • hs-cTnI水平升高者需加强心血管危险因素管理与随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: High-sensitivity cardiac troponin I (hs-cTnI) is an emerging biomarker for cardiovascular risk. We examined hs-cTnI as a predictor of mortality and cardiovascular outcomes in an Australian population-based cohort and evaluated if a sex difference exists. METHODS: Serum hs-cTnI was measured in the Busselton Health Study 1994/1995 Cohort (n=3939). Outcome measures were total and cardiovascular mortality, cardiovascular disease (CVD) and coronary heart disease (CHD) events, heart failure and stroke. RESULTS: Hs-cTnI was detectable (>1.2 ng/L) in 66.1% of participants (males 81.8%, females 54.4%) at baseline. There were 886 deaths (including 361 from CVD) and 940 CVD events during 20-year follow-up. Adjusting for Framingham Risk Score variables, hs-cTnI was a significant predictor of total mortality (HR (95% CI): 1.16 (1.09 to 1.24)), CVD mortality (1.33 (1.23 to 1.44)), CVD events (1.18 (1.11 to 1.25)), CHD events (1.11 (1.03 to 1.20)), heart failure (1.44 (1.31 to 1.58)) and stroke (1.13 (1.03 to 1.24)) per doubling of hs-cTnI at baseline. HRs remained significant in CVD-free individuals at baseline (n=3215), except for CHD events. There were no significant interactions between sex and hs-cTnI as a predictor of outcomes. Compared with individuals with hs-cTnI ≤1.2 ng/L, men with hs-cTnI ≥6.0 ng/L and women with hs-cTnI ≥4.0 ng/L had an HR of 2.18 (1.42 to 3.37) and 1.84 (1.30 to 2.62), respectively, for any CVD event, which persisted in the CVD-free subgroup. CONCLUSIONS: Cardiac troponin I, measured with a high-sensitive assay, is an independent predictor of fatal and non-fatal CVD events and may help identify at-risk individuals in a general population.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Zhu K, Knuiman M, Divitini M, et al. High-sensitivity cardiac troponin I and risk of cardiovascular disease in an Australianpopulation-based cohort. Heart. 2017. PMID: 29066610. doi:10.1136/heartjnl-2017-312093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。